The Effect of Androgen Deprivation Therapy Before Salvage Whole-gland Cryoablation After Primary Radiation Failure in XXXX Treatment.

@entity1 @entity323 @entity1949 @entity263 @entity322 @entity5 @entity9132 @entity1486
OBJECTIVE: To define the effects of @entity1949 ( @entity1949 ) used prior to salvage cryoablation (SC) for the treatment of recurrent @entity263 after radiation. METHODS: @entity1 from the Cryo On-Line Database registry undergoing SC after radiation failure were divided according to whether they had previously received or not received @entity1949 . Baseline characteristics including demographics and presalvage @entity5 risk were compared. Biochemical progression-free survival (bPFS) as defined by the Phoenix criteria was compared between the 2 groups as a whole and also in D'Amico risk-stratified subgroups. In addition, postsurgical complications such as @entity9132 , retention, @entity322 , and @entity323 were compared. RESULTS: Two groups consisting of 254 and 486 @entity1 with and without pre-SC @entity1949 were analyzed. The @entity1 who received @entity1949 were younger (P  = .003) and had higher presalvage D'Amico risks (P  <.001). The 5-year bPFS was 63.8% and 39.3% for the hormone-na  ve and the pre-SC @entity1949 @entity1 , respectively (P  <.001). On subgroup analysis, the difference in 5-year bPFS was significant only for @entity1 with a high D'Amico @entity5 risk (54.3% vs 30.5%; P  = .013). On multivariate analysis, presalvage @entity1486 (hazard ratio [HR], 1.7), Gleason score  >= 8 (HR, 2.5), and use of pre-SC @entity1949 (HR, 1.7) correlated with biochemical recurrence. Additionally, @entity1 receiving pre-SC @entity1949 experienced less urinary retention (P  = .001) and @entity322 (P  = .008) but were more likely to be impotent (P  = .010). CONCLUSION: @entity1 receiving @entity1949 before SC, especially those with high-risk prostate @entity5 , had worse 5-year bPFS. Added caution is needed when selecting @entity1 having previously received @entity1949 for salvage cryotherapy.
